0
0
The Health Ministry of India has recently revised its rules regarding the minimum sample size requirement for bioavailability and bioequivalence (BA/BE) studies, a key regulatory change affecting clinical research practices in the country. The latest amendment, issued as a corrigendum on October 31, 2025, sets the minimum sample size for these studies at 18 participants, replacing the earlier draft clause that limited the maximum sample size to 48. This update forms part of broader reforms aiming to simplify the clinical trial regulatory framework under the New Drugs and Clinical Trials (NDCT) Rules, 2019.
Key Developments in BA/BE Study Regulations
The Ministry of Health and Family Welfare (MoHFW) issued a corrigendum (G.S.R. 810(E)) modifying the earlier draft notification (G.S.R. 587(E)) published in August 2025. The original draft allowed BA/BE studies of orally administered drugs—excluding specific categories like cytotoxic, hormone, narcotic, psychotropic substances, drugs with a narrow therapeutic index, or drugs with highly variable pharmacokinetics—to be conducted after an online notification to the Central Licensing Authority, thereby eliminating the need for prior approval. The updated stipulation now mandates a minimum sample size of 18 for these studies, ensuring sufficient participant numbers for statistical reliability while facilitating streamlined study initiation.
Expert Commentary and Regulatory Context
Dr. Ramesh Verma, a clinical pharmacologist not involved with the drafting of the rules, notes that “The adjustment in sample size requirements aligns India’s clinical research protocols with international norms and balances the need for robust data with operational feasibility.” Historically, BA/BE studies typically enroll 18 to 36 healthy volunteers in crossover designs to evaluate the rate and extent of drug absorption, essential for confirming generic drug equivalence to branded products. The revised regulation helps standardize study design while reducing administrative burden.
The amendments are part of a larger initiative to promote ease of doing business in pharmaceutical research by cutting down approval wait times from 90 to 45 days, shifting certain approvals to notification-based systems, and reducing the volume of licensing applications by an estimated 50%. This is expected to accelerate drug development timelines and enhance India’s attractiveness as a destination for clinical trials and pharmaceutical innovation.
Implications for Public Health and Clinical Research
By setting a clear minimum sample size, the revision safeguards the scientific validity of BA/BE studies, crucial for ensuring that generic drugs approved in India meet quality and efficacy standards comparable to their branded counterparts. This move also encourages ethical research practices by requiring approval from ethics committees registered with the Central Licensing Authority, thereby protecting participant welfare.
From a practical standpoint, healthcare providers and consumers can be more confident that generics available in the market are substantiated by rigorous evidence. This supports broader goals of affordable access to safe and effective medications, an important public health priority given the burden of chronic and infectious diseases in the country.
Limitations and Considerations
While the minimum sample size of 18 is consistent with international conventions, there remains variability in BA/BE study designs based on drug characteristics and pharmacokinetic profiles. Some experts caution that more complex drugs may require larger or more specialized studies to adequately capture variability. Moreover, as the regulation facilitates faster study approval through notification rather than licensing, close monitoring of study conduct and quality assurance by regulatory authorities will be essential to maintain standards.
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
